-
Uncategorized2 weeks ago
Multiomics Mass Spec Workflows in Drug Discovery
Advances in end-to-end multiomics platforms and the underlying scientific knowledge now enable faster and more precise biomarker discovery, mechanistic insight generation, and therapeutic design—core drivers of...
-
Uncategorized2 weeks ago
ASCO: Summit reached with China lung data but new climb begins to prove global benefit
“King Keytruda’s reign continues,” analysts at BMO Capital Markets declared after Chinese data for Summit Therapeutics’ ivonescimab were revealed at the American Society for Clinical Oncology...
-
Uncategorized2 weeks agoSTAT+: Pharmalittle: We’re reading about pancreatic and lung cancer drugs, China biotech growth, and more
Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating because that oh-too-familiar routine of meetings, deadlines, and...
-
Uncategorized2 weeks ago
Moderna partners with CEPI on Ebola vaccine efforts amid outbreak in Africa
Riding a newfound surge of interest on infectious disease concerns, Moderna is linking up with a global vaccine foundation in hopes of developing a vaccine to...
-
Uncategorized2 weeks ago
ASCO: Biopharma has pancreatic cancer ‘surrounded’ as Immuneering’s drug adds 9 quality months
In addition to eliciting 17.3 months median overall survival vs. 8.5 months for patients given standard of care treatment in a prior study, Immuneering’s atebimetinib demonstrated...
-
Uncategorized2 weeks agoSTAT+: Servier to buy Edgewise Therapeutics’ muscular dystrophy drug
The French pharma company Servier said Monday that it would buy Edgewise Therapeutics’ muscular dystrophy business in a deal worth up to $2.65 billion. The centerpiece...
-
Uncategorized2 weeks ago
ASCO: Kelun-Merck ADC shines with differentiated overall survival in first-line lung cancer
Interim overall survival data on a TROP2 ADC from Merck and Chinese partner Kelun-Biotech provide support for the pharma’s big bet on its potential to help...
-
Uncategorized2 weeks agoTrust and regulation holding back AI in clinical trials
The use of AI in clinical trials is being held back by a lack of trust and regulatory uncertainty, professionals say. A poll from The Pistoia...
-
Uncategorized2 weeks agoOne Antibody, Fewer Scientific Surprises
Sponsored content brought to you by In biomedical research, promising programs rarely collapse for lack of scientific ambition. More often, they collapse under the weight of...
-
Uncategorized2 weeks agoSpatial Atlasing: Why Sensitivity Is the Real Frontier
Sponsored content brought to you by Cell atlasing efforts rest on a deceptively simple premise: To understand a tissue, you must find every cell in it,...
Laser‑Driven Phase Contrast Enhances Cryo‑EM Resolution of Small Proteins
STAT+: Updated: Tracking RFK Jr.’s promises to remake health in America
